Compagnie Lombard Odier SCmA’s GT Biopharma GTBP Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,667	Closed	-$12.1K	–	584
2023 Q3	$12.1K	Hold	1,667	–	–	﹤0.01%	508
2023 Q2	$15.6K	Hold	1,667	–	–	﹤0.01%	487
2023 Q1	$27.5K	Hold	1,667	–	–	﹤0.01%	498
2022 Q4	$45K	Hold	1,667	–	–	﹤0.01%	484
2022 Q3	$88K	Buy	1,667 +667	+67%	+$51K	﹤0.01%	406
2022 Q2	$90K	Hold	1,000	–	–	﹤0.01%	392
2022 Q1	$86K	Hold	1,000	–	–	﹤0.01%	393
2021 Q4	$92K	Buy	1,000 +500	+100%	+$74.8K	﹤0.01%	444
2021 Q3	$101K	Hold	500	–	–	﹤0.01%	430
2021 Q2	$233K	Buy	+500	New	+$208K	0.01%	325

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Compagnie Lombard Odier SCmA's GTBP Position: Q4 2023 in Review

Compagnie Lombard Odier SCmA sold out of GT Biopharma (GTBP) in Q4 2023, closing a stake of 1,667 shares — an estimated $12.1K sold.

Compagnie Lombard Odier SCmA first reported a position in GTBP in Q2 2021 and held it in 10 quarters. The position peaked at $233K in Q2 2021. 33 funds tracked by Wall St. Rank hold GTBP as of Q4 2023.

Compagnie Lombard Odier SCmA reported no remaining GT Biopharma position as of Q4 2023 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 1,667 GT Biopharma shares in Q4 2023, an estimated $12.1K.
Compagnie Lombard Odier SCmA first reported a position in GT Biopharma in Q2 2021 and held it in 10 quarters.
Compagnie Lombard Odier SCmA's GT Biopharma position peaked at $233K in Q2 2021.
33 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2023.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2023, filed 16 Jan 2024.